'Why isn't the neural tube defects rate lower?,' asks March of Dimes

DALLAS - June 19, 2001 - Researchers at UT Southwestern Medical Center at Dallas report that administering replacement estrogen via a skin patch is superior to oral estrogen replacement therapy in lowering blood pressure and sympathetic nerve activity - the neural control of blood pressure - in postmenopausal women.

The study, published in today's issue of Circulation, is the first to compare the effectiveness of oral and transdermal replacement therapies on sympathetic nerve activity in humans.

These findings suggest that how estrogen is administered is the key in optimizing the beneficial effects of estrogen replacement therapy on blood pressure, said Dr. Wanpen Vongpatanasin, assistant professor of internal medicine in hypertension and lead author of the study.

"Prevalence of hypertension is very low in young pre-menopausal women but increases markedly after menopause, suggesting a protective role of estrogen on blood pressure. Knowledge from this study may lead to an effective therapy to treat or prevent hypertension after menopause," she said.

Vongpatanasin and her colleagues reported that transdermal estrogen, or the estrogen patch, decreased nerve activity in postmenopausal women with normal blood pressure by 30 percent. The researchers also reported a small, but statistically significant, decrease in blood pressure in patients taking transdermal estrogen.

Both nerve activity and blood pressure were unaffected in patients taking oral estrogen. "This is an initial step that leads us to think that all estrogen preparations are not the same," Vongpantanasin said.

"This may be one of the reasons why large clinical trials failed to show a benefit of estrogen replacement therapy on blood pressure or any cardiovascular outcomes. It could very well be because only oral estrogen, the most popular preparation in the United States, has been used rather than transdermal estrogen."

Postmenopausal w

Contact: Michele Kling
March of Dimes Birth Defects Foundation

Page: 1 2 3

Related biology news :

1. Two warbler species find the West isnt big enough for both of them
2. Bigger isnt always better--especially if youre a rodent
3. Meow isnt language, but enough to manage humans
4. Caffeine in colas: The Real Thing isnt the taste
5. Knock knock knocking on rhythms neural doors
6. Molecule awakens and maintains neural connections
7. DHEA boosts growth rate of human neural stem cells
8. UC Berkeley scientists detail neural circuit that lets eye detect directional motion
9. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
10. The brain uses the same neural networks to engage in conscious and unconscious learning
11. Astrocytes play starring role in neural stem cell development

Post Your Comments:

(Date:4/1/2020)... ... 31, 2020 , ... Flagship Biosciences, providers of expert tissue ... team as Vice President Clinical Diagnostics. Geoff brings 25 years of experience in ... will lead the creation and implementation of diagnostic tissue tests utilizing Flagship’s unique ...
(Date:3/20/2020)... Conn. (PRWEB) , ... March 20, 2020 , ... ... the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), ... T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced ...
(Date:3/13/2020)... ... March 13, 2020 , ... ... Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. ... medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... ... March 31, 2020 , ... Carterra® Inc., the world ... (LJI), announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds ... the clinic as early as this summer. , La Jolla Institute for Immunology ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... located centrally in the midwest for high-quality, quick-turn, board-certified reporting. In an ... motivated, independent, professional team that is focused on incredible quality, turnaround time ...
(Date:3/19/2020)... ... March 17, 2020 , ... ... and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. ... ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s ...
(Date:3/13/2020)... Del. (PRWEB) , ... March 12, 2020 , ... ... collaboration with the APC Microbiome Ireland SFI Research Center (APC), a pioneer in ... on the body and play a significant role in human health, based at ...
Breaking Biology Technology:
Cached News: